Zentalis Pharmaceuticals, Inc. (ZNTL)
Develops experimental cancer drugs currently testing in clinical trials.
$4.54+0.01%Healthcare
StockGlow Score
Bullish
BearishBullish
1 year ago+238.7%
The outlook
ZNTL is trading near the middle of its 52-week range with strong technical positioning above both its 50- and 200-day moving averages. Analysts lean bullish with a "Buy" consensus, and the average price target sits roughly 47% above the current price. The stock shows solid upward momentum on recent technicals, though it's a smaller-cap biotech with concentrated coverage.
What’s behind the score
Analyst consensusBuy — 2.0 avg of 9 analysts
Price trendAbove its 50- & 200-day averages
52-week range58% of the way from its 52-week low to high
Price targetAvg target +47% vs current price
Analyst price target
~12-month · 9 analysts$6.67average target+46.9% vs now
Now $4.54
Low $4.00High $10.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$323.1M
52-wk high
$6.95
52-wk low
$1.21
50-day avg
$4.16
200-day avg
$2.87
Trailing P/E
—